These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 22142332)

  • 1. Effect of pegylated interferon-α-2a treatment on mental health during recent hepatitis C virus infection.
    Alavi M; Grebely J; Matthews GV; Petoumenos K; Yeung B; Day C; Lloyd AR; Van Beek I; Kaldor JM; Hellard M; Dore GJ; Haber PS;
    J Gastroenterol Hepatol; 2012 May; 27(5):957-65. PubMed ID: 22142332
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adherence to treatment for recently acquired hepatitis C virus (HCV) infection among injecting drug users.
    Grebely J; Matthews GV; Hellard M; Shaw D; van Beek I; Petoumenos K; Alavi M; Yeung B; Haber PS; Lloyd AR; Kaldor JM; Dore GJ;
    J Hepatol; 2011 Jul; 55(1):76-85. PubMed ID: 21145855
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of response-guided directly observed pegylated interferon and self-administered ribavirin for people who inject drugs with hepatitis C virus genotype 2/3 infection: The ACTIVATE study.
    Grebely J; Dalgard O; Cunningham EB; Hajarizadeh B; Foster GR; Bruggmann P; Conway B; Backmund M; Robaeys G; Swan T; Amin J; Marks PS; Quiene S; Applegate TL; Weltman M; Shaw D; Dunlop A; Hellard M; Bruneau J; Midgard H; Bourgeois S; Staehelin C; Dore GJ;
    Int J Drug Policy; 2017 Sep; 47():177-186. PubMed ID: 28624134
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Virological response in patients with hepatitis C virus genotype 1b and a high viral load: impact of peginterferon-alpha-2a plus ribavirin dose reductions and host-related factors.
    Yamada G; Iino S; Okuno T; Omata M; Kiyosawa K; Kumada H; Hayashi N; Sakai T
    Clin Drug Investig; 2008; 28(1):9-16. PubMed ID: 18081356
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Retrospective chart review to assess the relationship between depression and sustained virological response from interferon treatment for hepatitis C virus.
    Wackernah RC; Lou M; Park SH
    Clin Ther; 2011 Oct; 33(10):1400-5. PubMed ID: 21982383
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hepatitis C virus therapy with peg-interferon and ribavirin in Myanmar: A resource-constrained country.
    Hlaing NK; Banerjee D; Mitrani R; Arker SH; Win KS; Tun NL; Thant Z; Win KM; Reddy KR
    World J Gastroenterol; 2016 Nov; 22(43):9613-9622. PubMed ID: 27920482
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antiviral regimen complexity index as an independent predictor of sustained virologic response in patients with chronic hepatitis C.
    Galán RJ; Cidoncha EC; Martin MF; Rodriguez CC; Almeida CV; Verdugo RM
    J Manag Care Pharm; 2013; 19(6):448-53. PubMed ID: 23806058
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recruitment and follow-up of injecting drug users in the setting of early hepatitis C treatment: insights from the ATAHC study.
    Nguyen OK; Dore GJ; Kaldor JM; Hellard ME;
    Int J Drug Policy; 2007 Oct; 18(5):447-51. PubMed ID: 17854736
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of aging, glucose level, and HIV viral load on response to treatment with pegylated interferon plus ribavirin in HIV/HCV co-infected women.
    Nasta P; Maida I; Cattelan AM; Pontali E; Angeli E; Giralda M; Verucchi G; Caputo A; Iannacone C; Puoti M; Carosi G
    J Womens Health (Larchmt); 2015 Feb; 24(2):159-64. PubMed ID: 25682817
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Directly observed pegylated interferon plus self-administered ribavirin for the treatment of hepatitis C virus infection in people actively using drugs: a randomized controlled trial.
    Hilsden RJ; Macphail G; Grebely J; Conway B; Lee SS
    Clin Infect Dis; 2013 Aug; 57 Suppl 2():S90-6. PubMed ID: 23884072
    [TBL] [Abstract][Full Text] [Related]  

  • 11. OPERA: responses to peginterferon and ribavirin therapy in a subgroup of interferon-naïve patients with HIV/HCV genotype 2/3 co-infection in Italy.
    Bruno R; Cariti G; Nasta P; Capetti A; Ravasio V; Galli M; Raise E; Palmieri G; Iannacone C; Puoti M
    Liver Int; 2015 Jan; 35(1):120-9. PubMed ID: 25041136
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rapid virological response tailors the duration of treatment in hepatitis C virus genotype 3 patients treated with pegylated interferon alfa-2a and ribavirin in Pakistan.
    Gill U; Aziz H; Gill ML
    Int J Infect Dis; 2013 Nov; 17(11):e1017-21. PubMed ID: 23896656
    [TBL] [Abstract][Full Text] [Related]  

  • 13. OPERA: use of pegylated interferon plus ribavirin for treating HCV-HIV coinfection in interferon-naive patients.
    Carosi G; Bruno R; Cariti G; Nasta P; Gulminetti R; Galli M; Angarano G; Verucchi G; Pontali E; Capetti A; Raise E; Ravasio V; Maida I; Iannacone C; Caputo A; Puoti M
    Antivir Ther; 2014; 19(8):735-45. PubMed ID: 24583976
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacological interventions for acute hepatitis C infection: an attempted network meta-analysis.
    Kalafateli M; Buzzetti E; Thorburn D; Davidson BR; Tsochatzis E; Gurusamy KS
    Cochrane Database Syst Rev; 2017 Mar; 3(3):CD011644. PubMed ID: 28285495
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multicenter comparison of PEG-IFN α2a or α2b plus ribavirin for treatment-naïve HCV patient in Korean population.
    Jin YJ; Lee JW; Lee JI; Park SH; Park CK; Kim YS; Jeong SH; Kim YS; Kim JH; Hwang SG; Rim KS; Yim HJ; Cheong JY; Cho SW; Lee JS; Park YM; Jang JW; Lee CK; Sohn JH; Yang JM; Han S
    BMC Gastroenterol; 2013 Apr; 13():74. PubMed ID: 23627926
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adherence to response-guided pegylated interferon and ribavirin for people who inject drugs with hepatitis C virus genotype 2/3 infection: the ACTIVATE study.
    Cunningham EB; Hajarizadeh B; Dalgard O; Amin J; Hellard M; Foster GR; Bruggmann P; Conway B; Backmund M; Robaeys G; Swan T; Marks PS; Quiene S; Applegate TL; Weltman M; Shaw D; Dunlop A; Bruneau J; Midgard H; Bourgeois S; Thurnheer MC; Dore GJ; Grebely J;
    BMC Infect Dis; 2017 Jun; 17(1):420. PubMed ID: 28610605
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and efficacy of Hansenula-derived PEGylated-interferon alpha-2a and ribavirin combination in chronic hepatitis C Egyptian children.
    El Naghi S; Abdel-Ghaffar TY; El-Karaksy H; Abdel-Aty EF; El-Raziky MS; Allam AA; Helmy H; El-Araby HA; Behairy BE; El-Guindi MA; El-Sebaie H; Abdel-Ghaffar AY; Ehsan NA; El-Hennawy AM; Sira MM
    World J Gastroenterol; 2014 Apr; 20(16):4681-91. PubMed ID: 24782620
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Quality of Life and Social Functioning during Treatment of Recent Hepatitis C Infection: A Multi-Centre Prospective Cohort.
    Doyle JS; Grebely J; Spelman T; Alavi M; Matthews GV; Thompson AJ; Dore GJ; Hellard ME;
    PLoS One; 2016; 11(6):e0150655. PubMed ID: 27355323
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Response predictors and clinical benefits of hepatitis C retreatment with pegylated interferon and ribavirin in HIV/HCV coinfection.
    Peribañez-Gonzalez M; da Silva MH; Vilar FC; Seixas-Santos Nastri AC; Ferreira PA; Focaccia R; Mendes Correa MC
    Ann Hepatol; 2013; 12(2):228-35. PubMed ID: 23396734
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Virological responses during treatment for recent hepatitis C virus: potential benefit for ribavirin use in HCV/HIV co-infection.
    Grebely J; Hellard M; Applegate T; Petoumenos K; Yeung B; Feld JJ; Rawlinson W; Lloyd AR; George J; Kaldor JM; Dore GJ; Matthews GV;
    AIDS; 2012 Aug; 26(13):1653-61. PubMed ID: 22555168
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.